Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Cong-Xiao Liu"'
Autor:
Gabrielle P. Dailey, Christopher A. Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C. Hobeika, Amanda Summers, Robert D. Marek, Michael A. Morse, Herbert K. Lyerly, Erika J. Crosby, Zachary C. Hartman
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment
Externí odkaz:
https://doaj.org/article/e1e721b8aa614715a2839e38dfea6881
Autor:
Xiao Yang, Tao Wang, Michael A Morse, Takuya Osada, William Gwin, Herbert Kim Lyerly, Cong-Xiao Liu, Pankaj Agarwal, Hiroshi Nagata, Erika J Crosby, Pei Zhong, Shinya Abe, Yoshiyuki Inoue, Kensuke Kaneko, Chaitanya R Acharya, Joshua Snyder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/f1a40627b3444ff2afb9da9c50ee6a96
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background The advent of immune checkpoint blockade antibodies has demonstrated that effective mobilization of T cell responses can cause tumor regression of metastatic cancers, although these responses are heterogeneous and restricted to certain his
Externí odkaz:
https://doaj.org/article/6cdeb5056cb243e1839fdc148a8a38ff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently,
Externí odkaz:
https://doaj.org/article/80c451e5a9a545369460b7eb5acca6ab
Autor:
Erika J. Crosby, Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, Alan J. Korman, Michael A. Morse, Kenneth Gouin, Simon R. V. Knott, H. Kim Lyerly, Zachary C. Hartman
Publikováno v:
OncoImmunology, Vol 7, Iss 5 (2018)
Triple-negative breast cancer (TNBC) is an aggressive and molecularly diverse breast cancer subtype typified by the presence of p53 mutations (∼80%), elevated immune gene signatures and neoantigen expression, as well as the presence of tumor infilt
Externí odkaz:
https://doaj.org/article/c1f12874871c4c10bce8a2bcabe257fc
Autor:
Takuya Osada, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, Hongtao Guo, Xiao-Yi Yang, Cong-Xiao Liu, Kensuke Kaneko, Gloria Broadwater, H. Kim Lyerly
Publikováno v:
OncoImmunology, Vol 6, Iss 6 (2017)
Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies. As such, inhibiting HER3 could have broad appl
Externí odkaz:
https://doaj.org/article/e1cab1a1d6b840e4b61b5ec0f6c44701
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary Figure 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d9f7fafcbe4db7fdd5257499cd6572
https://doi.org/10.1158/1078-0432.22477275
https://doi.org/10.1158/1078-0432.22477275
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aeead83f5865375b9ce73a6c708588f
https://doi.org/10.1158/1078-0432.22477263
https://doi.org/10.1158/1078-0432.22477263
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Purpose:Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had broad success as monotherapies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c78a9a45a6376562600743e9c01e68
https://doi.org/10.1158/1078-0432.c.6529605.v1
https://doi.org/10.1158/1078-0432.c.6529605.v1
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f90129615fc3bcb3641865d50082013
https://doi.org/10.1158/1078-0432.22477266.v1
https://doi.org/10.1158/1078-0432.22477266.v1